Protagonist Therapeutics and Takeda Pharmaceutical Company entered a strategic partnership regarding the Rusfertide drug candidate, while Citi initiated coverage with a Buy rating.
6 reports, 2 independent
Updated Sep 6
Gone quiet
- Reports
- 6
- Developments
- 4
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Protagonist Therapeutics and Takeda Pharmaceutical Company entered a strategic partnership regarding the Rusfertide drug candidate, while Citi initiated coverage with a Buy rating.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.J&J, Protagonist, and Takeda partnered on ICOTYDE and are seeking approval for both ICOTYDE and rusfertide.1 source
- Protagonist Therapeutics and Takeda secured exclusive worldwide commercialization rights for rusfertide, which was approved by the FDA for polycythemia vera in adults.Sub-event
Protagonist Therapeutics is seeking a decision from the FDA on rusfertide.1 source
- Protagonist Therapeutics and Takeda partner on Rusfertide; Citi initiates Buy rating.
Keep exploring
The entities involved
-
Protagonist Therapeutics (United States)
company in Milpitas, United States
Nothing else this week.
-
Takeda Pharmaceutical Company
Japanese pharmaceutical company
Nothing else this week.
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Related events
Coverage
Newest first; wire copies grouped- yahoo.com
- pr-inside.com
- Unknown outlet